Vera rises as FDA agrees to review late-stage kidney drug data for full approval
BUZZ-Vera rises as FDA agrees to review late-stage kidney drug data for full approval ** Shares of Vera Therapeutics VERA.O rise 2.9% to $34.92 premarket
** VERA says it has aligned with the U.S. Food and Drug Administration to speed up plans that could lead to full approval of its experimental kidney disease drug, atacicept
** Says the FDA has agreed to review key data from a late-stage study earlier than planned, with results now expected in Q3 2026, instead of 2027
** Vera plans to apply for supplemental application in Q4 based on additional trial data
** Atacicept is already under review by the FDA for accelerated approval in patients with IgA Nephropathy, with a decision expected on July 7
** IgA nephropathy is an autoimmune condition that can lead to kidney failure
** Up to last close, stock down about 33% YTD
(Reporting by Siddhi Mahatole)
Recent news on Vera Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Forgent Power, Vera Bradley, Wells Fargo
U.S. STOCKS ON THE MOVE-Forgent Power, Vera Bradley, Wells Fargo
U.S. STOCKS ON THE MOVE-Eli Lilly, Waystar, Wells Fargo
U.S. STOCKS ON THE MOVE-Eli Lilly, Waystar, Sysco
Vera Therapeutics gains after kidney disease drug meets goals in confirmatory trial